Contact a rep button
contact a rep

stay connected!

Fill in the required fields to stay up to date with news and announcements about VPRIV.
*Required Field

One or more required fields are invalid.

Please review and submit this form again.

thank you!

You have been successfully signed up to receive
communications from Takeda

Click here to unsubscribe


You understand your patients and the various stages they’ll experience in their individual journeys. We understand your needs in supporting your patients on their journey. Our goal is to help make sure you’re not just ready, you’re VPRIV Ready.
Male Doctor with patient hero blob
Blue blob Purple blob
  • VPRIV should be administered under the supervision of a healthcare professional1
  • Diluted VPRIV should be administered through an in-line low protein-binding 0.2 or 0.22 µm filter. VPRIV should not be infused with other products in the same infusion tubing. The compatibility of VPRIV in a solution with other products has not been evaluated1

Attach IV tubing to the bag of VPRIV solution. IV tubing should have an in-line filter in place.1

Attaching IV tube to bag of VPRIV

Use normal saline to prime tubing and expel all air.

Injecting saline to expel air

Set the infusion to administer at the rate prescribed. A 60-minute infusion is recommended.1

Timer for 60 minute infusion

Select the IV infusion site; this will vary by patient and may include: antecubital, wrist, or hand veins, or a central venous catheter. Follow your facility’s policies for IV insertion, medication infusion, and disposal of biohazardous waste.

Hand/wrist (infusion site)

Begin VPRIV therapy infusion with the flow-regulating device or IV pump. Monitor the patient regularly. If anaphylactic or other acute reactions occur, discontinue VPRIV immediately and initiate appropriate medical treatment.1

Please see Section 5.1 of the Warnings and Precautions section of the Prescribing Information for important information on hypersensitivity reactions.
Dosing and infusion guide


Hypersensitivity reactions, including anaphylaxis, have occurred. The most serious adverse reactions in patients treated with VPRIV were hypersensitivity reactions.

Hypersensitivity reactions were the most commonly observed adverse reactions in patients treated with VPRIV in clinical studies. Patients were not routinely pre-medicated prior to infusion of VPRIV.